


A-52711

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A composition of matter of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^3)_e-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently randomized Ang-2 binding peptide sequences of ~~pharmacologically active peptides~~;


L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither X^1 nor X^2 is a native protein.

2. (original) The composition of matter of Claim 1 of the formulae




or



3. (original) The composition of matter of Claim 1 of the formula



4. (original) The composition of matter of Claim 1 of the formula



5. (original) The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.

6. (original) The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.

7. (original) The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

Claims 8 - 21 (canceled).

A-52711

22. (currently amended) A DNA encoding a composition of matter of ~~any of Claim[s] 1 to 21.~~
23. (original) An expression vector comprising the DNA of Claim 22.
24. (original) A host cell comprising the expression vector of Claim 23.
25. (original) The cell of Claim 24, wherein the cell is an E. coli cell.
26. (currently amended) A process for preparing an Ang-2 binding pharmacologically active compound, which comprises
- a) selecting at least one randomized Ang-2 binding peptide that modulates the activity of a protein of interest; and
 - b) preparing an Ang-2 binding pharmacologic agent compound comprising at least one Fc domain covalently linked to at least one amino acid sequence of the selected peptide or peptides.
27. (original) The process of Claim 26, wherein the peptide is selected in a process comprising screening of a phage display library, an E. coli display library, a ribosomal library, or a chemical peptide library.

Claims 213 - 42 (canceled).

43. (original) The process of Claim 26 wherein the Fc domain is an IgG Fc domain.
44. (original) The process of Claim 26, wherein the vehicle is an IgG1 Fc domain.
45. (original) The process of Claim 26, wherein the vehicle comprises the sequence of SEQ ID NO: 2.
46. (original) The process of Claim 26, wherein the compound prepared is of the formula
- $$(X^1)_a-F^1-(X^2)_b$$
- and multimers thereof, wherein:
- F¹ is an Fc domain;
- X¹ and X² are each independently selected from -(L¹)_c-P¹, -(L¹)_c-P¹-(L²)_d-P², -(L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³, and -(L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³-(L⁴)_f-P⁴


A-5271

P^1 , P^2 , P^3 , and P^4 are each independently sequences of pharmacologically active peptides;
 L^1 , L^2 , L^3 , and L^4 are each independently linkers; and
 a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1.


47. (original) The process of Claim 46, wherein the compound prepared is of the formulae




or



48. (original) The process of Claim 46, wherein the compound prepared is of the formulae



or



49. (original) The process of Claim 46, wherein F^1 is an IgG Fc domain.

50. (original) The process of Claim 46, wherein F^1 is an IgG1 Fc domain.

51. (original) The process of Claim 46, wherein F^1 comprises the sequence of SEQ ID NO: 2.